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Pharmacovigilance  is essential  for developing  reliable  information  on  the  safety  of  herbal  medicines
as  used  in Europe  and  the  US. The  existing  systems  were  developed  for  synthetic  medicines  and  require
some  modiﬁcation  to address  the  speciﬁc  differences  of  medicinal  herbs.  Traditional  medicine  from  many
different  cultures  is used  in  Europe  and  the  US  which  adds  to  the  complexities  and difﬁculties  of  even
basic  questions  such  as  herb  naming  systems  and chemical  variability.  Allied  to  this  also  is the  percep-
tion  that  a ‘natural’  or herbal  product  must  be safe  simply  because  it is not  synthetic  which  means  thaterbal medicine
harmacovigilance
rug safety
the  safety  element  of  monitoring  for such  medicines  can  be  overlooked  because  of the  tag associated
with  such  products.  Cooperation  between  orthodox  physicians  and traditional  practitioners  is  needed
to bring  together  the  full  case  details.  Independent  scientiﬁc  assistance  on  toxicological  investigation,
botanical  veriﬁcation  can  be  invaluable  for full  evaluation  of  any  case  report.  Systematic  pharmacovigi-
lance  is  essential  to build  up  reliable  information  on  the  safety  of  herbal  medicines  for the  development
of  appropriate  guidelines  for  safe  effective  use.
© 2012 Elsevier Ireland Ltd. Open access under CC BY-NC-ND license.. Introduction
Pharmacovigilance is deﬁned as ‘the study of the safety of mar-
eted drugs under the practical conditions of clinical usage in
arge communities’ (Mann and Andrews, 2002). The objective is to
xtend safety monitoring and detect drug adverse events that have
reviously been unrecognised despite evaluation in clinical trials.
lthough these methods were developed for monitoring pharma-
eutical medicines they are also used for additional evaluation of
he safety of other medicinal products including herbals, blood
roducts, vaccines and even medical devices.
As the use of herbal medicines has increased, so too have
he reports of suspected toxicity and adverse events. Such
nwanted reactions can be due to (i) side effects (usually
etectable by pharmacodynamics and often predictable); (ii) reac-
ions occurring as a result of overdose, overduration, tolerance,
ependence-addiction (detectable either by pharmacodynamics
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E-mail addresses: Debbie Shaw@talk21.com (D. Shaw), pduez@ulb.ac.be
D. Pierre), e.m.williamson@reading.ac.uk (W.  Elizabeth),
elvin.Chan@sydney.edu.au (C. Kelvin).
378-8741     ©  2012 Elsevier Ireland Ltd. 
oi:10.1016/j.jep.2012.01.051
Open access under CC BY-NC-ND license.or pharmacovigilance), (iii) hypersensitivity, allergic and idiosyn-
cratic reactions (detectable by pharmacovigilance), (iv) mid-term
and long-term toxic effects including liver, renal, cardiac and neuro-
toxicity also genotoxicity and teratogenicity (detectable by in vitro
and in vivo toxicological studies or by pharmacovigilance). As
many herbal products on the market have not been thoroughly
tested for their pharmacology and toxicology, pharmacovigilance
has paramount importance in detecting unwanted reactions.
In addition there is an ongoing problem with unexpected toxi-
city of herbal products due to quality issues, including use of poor
quality herbal material, incorrect or misidentiﬁed herbs, incor-
rect processing methods, supply of adulterated or contaminated
herbs or products (Shaw, 2010a). These quality issues can be
addressed to some degree by improved regulation requiring GMP
standards for manufacturing. However medicinal herbs/products
come from many countries with differing manufacturing standards
and enforcement of regulations so poor quality products are likely
to remain a problem.
The safety of herbal medicines has become an issue for the reg-
ulatory authorities, as serious effects have been reported, including
hepatotoxicity, renal failure and allergic reactions (Perharic et al.,
1995; Nortier and Vanherweghem, 2007). The World Health Organ-
isation, recognising the growing importance of the use of herbal
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edicines worldwide developed guidelines for the monitoring of
erbal safety within the existing pharmacovigilance framework
WHO, 2004).
. Challenges of herbal pharmacovigilance
Herbal medicines in Europe come from all traditions including
hinese, Indian, north and south American and African systems as
ell as that of European systems. This diversity adds to the chal-
enges of herbal pharmacovigilance including basic questions such
s deﬁning the most appropriate herb naming system (botanical,
ommon, pharmaceutical name or herbal drug name) and valida-
ion of the botanical identity of the herbal ingredients. These are
ot normally an issue with monitoring synthetic medicines. Some
f these questions, such as naming issues or adulterations, do not
t easily into the existing systems of pharmacovigilance or the
lectronic data systems that were developed for pharmaceuticals
DynPage, UMC). However, although some modiﬁcations may  be
eeded, developing separate systems for herbals is not the answer
s this is likely to add complications and cause confusion if differ-
nt forms or systems are used with the risk of reducing reporting
ates further (Menniti-Ippolito et al., 2008). As a good example of
armonisation, the Uppsala Monitoring Centre (UMC) takes ADR
eports from over 100 countries around the world and in 2010
heir database contained over 4 million reports, of which approx
1,000 included herbal or natural products (UMC, 2011). These
re all incorporated in a single database with review of suspected
ignals carried out by experts in relevant ﬁelds.
.1. Speciﬁc challenges
Unlike synthetic medicines, herbal medicines are typically
hemically rich and complex products and not isolated single com-
ounds. A number of factors can inﬂuence the qualitative and
uantitative chemical proﬁle including:
Geographical origin – climate, soil, photoperiod.
Genotype.
Parts of the plant – leaves, stems, root, root bark, etc.
Harvesting time (year, season, time of day) and conditions.
Storage, processing, extraction.
Combinations of herbs and/or processing of the combined herbs
as medicines.
As standardisation of herbs relative to the active compounds is
arely performed, this intrinsic variability results in products that
ay  be quite different and not necessarily bioequivalent even when
rom the same single herbal ingredients (Loew and Kaszkin, 2002).
ombining reports of adverse effects (or efﬁcacy) requires careful
valuation of the differences or similarities of the chemistry or bio-
ogical activity; however, if looking for safety signals for further
nvestigation then a potentially useful approach might be to study
roups of herbs containing similar compounds.
.1.1. Herbal medicines and dietary supplements
The classiﬁcation and regulation of herbal products may
ary between different countries/jurisdictions. In the EU they
re classiﬁed as herbal medicines (regulatory implications) with
equirements for safety and quality standards. Some herbs may  be
upplied as food supplements. In the US, herbal products are clas-
iﬁed as dietary supplements or botanicals, not medicines. Quality
ill vary although GMP  requirements were issued by the FDA in
007. Pharmacovigilance reporting is not compulsory for manu-
acturers.
There are subtleties in the legal differentiation between food
upplement and herbal medicine. But broadly a medicinal productacology 140 (2012) 513– 518
is deﬁned as ‘any substance or combination of substances presented
as having properties for treating or preventing disease in human
beings’. In contrast a food supplement cannot claim to treat or
prevent disease or contain a pharmacologically active substance.
This can be a complex area with the same herb being supplied as a
herbal medicine but also as an ingredient in a dietary supplement.
There are regulatory implications. In Europe, herbal medicines are
registered under two directives, either ‘well-established use’ or
‘traditional herbal medicinal products’ both of which have signiﬁ-
cant requirements for quality (GMP) and safety (amongst others).
Food supplements do not have the same legal requirements for
quality control.
The deﬁnition of a herbal product as a food or medicine may
therefore have considerable impact for pharmacovigilance.
2.2. Nomenclature and what was used
Adverse reaction reports, whether submitted to regulatory
authorities or published in the medical literature, are meaning-
less if the medicinal herb(s) or ingredients in a product cannot be
identiﬁed. Names for medicinal herbs include the Latin scientiﬁc
name, the common or vernacular name, the pharmaceutical name
or pharmacopoeal name or the speciﬁc herbal drug names (as used
in Traditional Chinese Medicine (TCM)). Herbal prescriptions, prod-
uct packaging or labels may  have one or more of these (occasionally
no label) depending on source and regulatory status of the product.
These have to be interpreted with care as even the scientiﬁc names
may  have synonyms.
The common or vernacular name is the least precise and the
same name may  be used for plants from different genera or species
and so should be avoided if possible. In Europe and US however, the
common name is frequently the term of reference, although the EU
guidelines require the Latin scientiﬁc name on the labelling. If the
product is of pharmacopoeial quality then the identity of the species
and plant part will be deﬁned in the European Pharmacopoeia
(PhEur). The common name may  be misleading or confusing if used
on crude plant material or unlicensed herbal medicines that are not
PhEur compliant. To avoid ambiguity it is desirable that the genus,
species and part of the plant are listed somewhere on the product
or packaging of the crude material.
Unfortunately a botanically correct label does not necessarily
conﬁrm that the product contains what is listed on the label. In cases
of serious adverse reactions where speciﬁc toxins are suspected
then laboratory analysis of the product/herb may  be advisable to
verify the reports.
2.2.1. Initiatives to address nomenclature and quality issues
There is currently no single reference list of medicinal plants
which presents an authoritative view on their current scientiﬁc
name and linking all synonyms of those plants that are found in
the literature. The only names that are standardised are Latin sci-
entiﬁc names (e.g. Bupleurum chinense DC.); their standardisation is
achieved though the ‘International Code of Nomenclature of algae,
fungi, and plants’ (ICN formerly ICBN).
A new initiative, the Medicinal Plants Names Index (MPNI)
underway at the Royal Botanic Gardens Kew will address
this issue (http://www.kew.org/science-research-data/directory/
projects/MPNI.htm). Working with a wide range of stakeholders,
one of this project’s main aims is to develop an authoritative index
to scientiﬁc plant names mapped to frequently used vernacular,
trade and pharmacopoeia names in order to support the develop-
ment of global, industry-wide medicinal data standards. This is a
3-year project (funded by Wellcome Trust) and will be accessed
freely over the internet with a range of other information services
being developed tailored to different needs.
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The UMC has worked with the Royal Botanic Gardens Kew
nd Uppsala University to develop appropriate standardisation and
ross-referencing of herbal names for their database to enable
nternational reporting of herbal ADRs. Review of potential signals
n the UMC database clearly shows the challenges and issues of
erbal pharmacovigilance, from identifying what was used (plant,
lant part, extract, dose) to clinical information available from dif-
erent countries. The UMC  has subsequently developed the WHO
erbal Dictionary an international reference source of herbal prod-
cts designed to be used for coding and analysis of drug safety data
oth pre and post marketing.
There are a number of initiatives to address herbal identiﬁcation
nd set quality standards. In addition to individual country pharma-
opoeias (e.g. British Pharmacopoeia) the European Pharmacopoeia
as an extensive programme of herbal monographs under develop-
ent including herbs from China and the Indian sub-continent. In
ddition the European Medicines Agency is also developing herbal
onographs. Herbal monographs have also been published by the
merican Herbal Pharmacopoeia, USP and the WHO  (5 volumes).
These monographs can deﬁne the standards for herb qual-
ty however to be effective these require appropriate regulation
nd enforcement to ensure implementation. In Europe, there is
 requirement for GMP  of all registered herbal products (well-
stablished use or traditional herbal products). Although this
hould improve the overall quality of herbal products available on
he market, less scrupulous dealers may  sell poor quality products
hrough the internet, mail order or other unregulated supply routes.
roducts sold as foods or food supplements will also avoid the GMP
equirements.
.3. Source–users of herbal medicine
Surveys have shown that consumers tend to self-prescribe
erbal medicines without consulting a professional herbal practi-
ioner or other health professional (Barnes et al., 1998; Ipsos Mori,
008). Products can be bought over-the-counter from pharmacies,
upermarkets, markets or the internet without any consultation
ith a health professional. Herbal medicines are prescribed by
rthodox medical professionals in few European countries (e.g.
ermany). Consumers may  not be aware that adverse effects of
erbal medicines can be reported to their general practitioner or
now how to report to regulatory authorities. In addition, con-
umers may  not associate the herbal product with the effect. A
umber of studies have shown that consumers are reluctant to
dmit to their physician that they have been using herbal medicines
Barnes, 2003).
Some consumers will consult herbal practitioners, but at present
egulations as to who can supply herbal medicines vary consid-
rably around Europe. Training and practice standards vary from
ighly trained professionals to untrained and unregulated individ-
als.
. Identifying adverse reactions
The classiﬁcation of types of adverse reactions is well estab-
ished in orthodox medicine and applies equally to herbal medicine.
dverse reactions are classiﬁed as (Edwards and Aronson, 2000):
Type A (acute/augmented); dose related and explained by phar-
macology of herbs.
Type B (bizarre/idiosyncratic); not dose related or predictable by
pharmacology.
Type C (chronic/cumulative): cumulative effect.
Type D (delayed onset) carcinogenic, genotoxic.acology 140 (2012) 513– 518 515
The safety of herbs is mostly based on empirical experience and
is effective in identifying acute toxicity with a rapid onset of symp-
toms within hours or days of using any herbal medicines. However
this traditional experience is not effective at identifying herb(s) that
cause cumulative, chronic or delayed toxicity. If the ﬁrst signs of
adverse effects are not recognised until months or years after start-
ing or even stopping use of the herbs/drugs the use of the herbs is
likely to be forgotten with such a delay.
Aristolochic acid nephropathy (AAN) is a very good example
of chronic toxicity (Type C). The effects are cumulative and renal
symptoms can be delayed for 2 years after stopping use of the
herbs (Reginster et al., 1995). Various species of Aristolochia have
been used in the traditional medicines of many countries (Heinrich
et al., 2009) (Aristolochia manshuriensis Kom and Aristolochia fangchi
Y.C. Wu  ex L.D. Chou & S.M. Hwang in Chinese medicine) although
aristolochic acids were known to have the potential to cause renal
toxicity. It was only because of the cluster of cases in Belgium
with detailed follow-up that the pattern of toxicity was recog-
nised and characterised with full histological description, details of
progression of the disease and possible development of urothelial
carcinomas (Reginster et al., 1995; Lemy et al., 2008).
Idiosyncratic reactions (Type B) can occur within days or weeks
of starting use of a medicine but are difﬁcult to identify as these are
not predictable, neither dose nor time dependent and are not nec-
essarily related to pharmacological activities but can result from
formation of reactive metabolites and immune-mediated reac-
tions (Edwards and Aronson, 2000). Such reactions occur rarely
(>1:10,000 and <1:1000) but are signiﬁcant as they may  be serious
or even fatal (CIOMS, 1995). Drug-induced hepatotoxicity is often
due to an idiosyncratic reaction. It is difﬁcult to conﬁrm single case
reports of suspected herbal toxicity which may  be due to idiosyn-
cratic reactions as symptoms may  be non-speciﬁc and there is no
clearly identiﬁable toxic compound that can be measured in labo-
ratory analysis. Such rare adverse reactions will not be recognised
without a formal reporting system.
4. Pharmacovigilance methods
A range of methods are used for post marketing monitoring
of drug safety including spontaneous reporting and prescrip-
tion event monitoring (DynPage UMC). These methods can be
used for monitoring herbal safety but require modiﬁcation to
address speciﬁc challenges such as botanical nomenclature, quality,
adulteration, labelling issues, prescriber/reporter differences and
under-reporting.
4.1. Spontaneous reports
Safety of medicines is commonly monitored through sponta-
neous reporting systems. There are subtle differences between
countries but the principles are the same. Standardised forms are
used for reporting of suspected adverse reactions to the regulatory
authorities by medical professionals, including physicians, phar-
macists, nurses and in some countries, by consumers (McLernon
et al., 2010). The reports are of ‘suspected’ adverse reactions, and
a reporter does not have to conﬁrm the association between drug
and effect. Such causality is assessed on a case-by-case basis by
the reporting centres. Statistical methods are used to identify dis-
proportionate reporting rates which can lead to a safety signal. A
‘signal’ only indicates an adverse effect of interest and one that
requires further evaluation and investigation – the link to the drugSpontaneous reports are more likely to be effective where
products are regulated as medicines and also where products are
supplied by health professionals who  are well informed in the use
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f this reporting system. Consumers may  not be aware of the impor-
ance of reporting adverse effects (McLernon et al., 2010).
In the US where herbal medicines/natural products are supplied
s dietary supplements, health professionals and consumers can
eport suspected adverse reactions to the FDA MedWatch scheme.
n the UK the spontaneous reporting system is referred to as the
yellow card’ scheme; other countries such as Australia have blue
ards. In the UK the yellow card was modiﬁed to allow for the inclu-
ion of herbals in 2000. However there are still problems regarding
ccurate ingredient lists, botanical naming of the medicinal herbs,
rocessing and product quality.
In the UK the Medicines and Healthcare Products Regulatory
gency receive about 20,000 yellow card reports per annum but
his includes only about 100 herbal reports. Despite efforts to
mprove reporting by extending to nurses, pharmacists and con-
umers there has not been any signiﬁcant increase in herbal reports.
ountries including Sweden and Italy have carried out studies on
erbal ADRs (Menniti-Ippolito et al., 2008; Jacobsson et al., 2009).
Because there are few ‘yellow card’ herbal reports in the UK, it
s relatively easy to identify adverse effects of concern by evalua-
ion of the individual reports without waiting for statistical signal
etection.
Where medicines are regulated (e.g. licensed as well-
stablished or traditional herbal medicinal product in Europe) then
anufacturers have pharmacovigilance obligations under Euro-
ean directives and perhaps additional National regulations. These
equirements are the same for orthodox and herbal medicines.
his includes timeframes and other reporting requirements for
nforming the regulatory authorities of any reports of unwanted
r unexpected side effects of their products. Unlicensed or unregu-
ated products or dietary supplements do not have to comply with
his directive.
.2. Problems with spontaneous reports
Underreporting is a well known problem with spontaneous
eporting systems (Hazell and Shakir, 2006). It is thought that this
s likely to be a greater problem with herbal medicines. Factors
ontributing to under-reporting of herbal ADRs include:
Lack of association between herb and adverse effect.
Patient stops using the herbal medicine when they feel unwell.
Physician/patient unaware that herbal ADRs should be reported.
Physician unaware of the use of herbal medicines as patient does
not consider herbal and nutritional products to be ‘medicines’
and does not disclose use (Barnes, 2003; Williamson et al., 2009).
The usefulness of any report of adverse effects is dependent on
nowing what herb/product was used. This relies on the accurate
dentiﬁcation of the product/herb by the reporter. If inadequate
ames are used this can lead to confusion. For example if only ‘gin-
eng’ is used in a report this may  refer to Panax ginseng C.A. Mey
r Panax quinquefolius (Burk.) F.H. Chen. But it may  also refer to a
ange of other plants that are also labelled as ‘ginseng’ – Eleuthero-
occus senticosus (Rupr. & Maxim) Maxim (Siberian ginseng) or the
nrelated Withania somnifera (L.) Dunal (Indian ginseng).
The quality of ADR reports can be improved by collaboration
ith pharmacognosy departments, botanic gardens or other tox-
cological units. In the UK the Chinese Medicine Advisory Service
ssists with enquiries on suspected herbal ADRs. Through collab-
ration with the Royal Botanic Gardens Kew, the identity of the
hinese medicinal herbs can be veriﬁed. When ADRs are published
n medical journals or submitted to the authorities then there is
ome conﬁdence in the botanical identity. In Hong Kong the Hospi-
al Authority Toxicology Reference Laboratory at Princess Margaretacology 140 (2012) 513– 518
Hospital also undertakes multidisciplinary investigation of cases of
herbal toxicity.
Well established use or products registered under the Tradi-
tional Herbal Medicinal Product Directive (THMPD) will have brand
name and the correctly listed constituents. Getting accurate lists
of ingredients is problematic for unregulated/unlicensed products.
Poor quality products are a continuing concern as there is no assur-
ance that the product contains the ingredients listed on the label.
Herbal products adulterated with pharmaceutical medicines for
slimming (e.g. sibutramine), inﬂammatory conditions (steroids) or
erectile dysfunction (sildenaﬁl) are an international problem. In
a review of herbal safety alerts for 2010, we  found that pharma-
ceutical contamination or adulteration accounted for 336 of 390
warnings that were issued by regulatory authorities in UK, US,
Canada, Singapore, Hong Kong and Australia.
With low numbers of ADR reports in a single country, then
herbal signals of interest may  not be identiﬁed, especially for reac-
tions that are rare. The WHO  Collaborating Centre for Monitoring
Drug Safety (UMC) seeks to address this problem by collating
ADR reports from over 100 countries around the world. By early
2011 their database contained over 6 million drug and herbal
reports (UMC, 2011). This is the largest repository of such reports.
They have attempted to address the nomenclature issues as herbal
reports come from countries with different systems of traditional
medicine.
However because of the variability of the composition of differ-
ent herbal products caution is needed when combining reports on
a single herb/product. But groups of herbs with similar chemical
composition can be used to identify signals for further study.
5. Monitoring for herb–drug interactions
There is a perception that herbal medicines are safe, even if
taken at the same time as prescription drugs (Delgoda et al., 2004).
Herbs may  be used to treat the primary condition or to reduce
the side effects of their conventional treatment. Under-reporting
of suspected interactions between herbs and drugs is of increasing
concern and arises from the same reasons as under-reporting of
herbal ADRs.
The particular problems that need to be addressed are those that
may  affect speciﬁc patient groups where the incidence of combin-
ing orthodox and herbal medicine use is thought to be high, and the
risk of interaction signiﬁcant, such as in cancer patients. However
any patients who  are on drug regimes involving potent medicines
metabolised by cytochrome P450 enzymes or where bioavailability
is affected by P glycoprotein are at increased risk of experiencing
herb–drug interactions.
Adverse reactions due to interactions may not be recognised
if the physician or other health professional is not aware of the
concomitant use of medicinal herbs (Giveon et al., 2004; Goldstein
et al., 2007). Adverse reactions due to drug interactions are rela-
tively common although largely preventable. The UMC  has recently
undertaken studies to show that pharmacokinetic and pharma-
codynamic drug interactions can be detected in their database
(Strandell et al., 2011). As this study develops it is hoped that
herb–drug interactions may  also be investigated.
6. Other methods of monitoring
Prescription event monitoring (PEM) is a non-interventional
hypothesis generating method for studying a drug once it is placed
on the market, through monitoring of individual prescriptions. In
the UK a modiﬁed protocol for using PEM for herbal medicines
has been developed based on monitoring prescriptions from herbal
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ractitioners. It is a useful method for investigating speciﬁc safety
oncerns on frequently used medicinal herbs (Barnes, 2003).
Intensive monitoring schemes can be an extension of the spon-
aneous reporting schemes and are used to stimulate reporting on
peciﬁc medicines. In Thailand there is an extensive list of regis-
ered herbal medicines that are also used in hospital settings. They
sed intensive monitoring on 9 different herbal products where
here was a need for further safety information (Saokaew et al.,
011).
Another source of pharmacovigilance and safety information on
erbal medicines is the Poisons Control Centres (Dennehy et al.,
005; Gryzlak et al., 2007). In Europe and US these centres take
nquiries where there are concerns about the safety of a prod-
ct or where there is a suspected poisoning. These enquiries are
ot necessarily formal reports so supporting information, includ-
ng product details, time course and dosage may  be lacking. Often
he patients may  have taken an acute or chronic overdose and are
eeking medical attention; this may  not yield useful information
n medium- or long-term toxicities. Poisons Control Centres are
n important source for dietary supplement ADRs in the US as was
hown by a study carried out in 2008 which revealed that the pri-
ary reporting portal MedWatch, received fewer reports than the
oison centres (Gardiner et al., 2008).
Other pharmacoepidemiological methods for detailed investi-
ation of drugs that can also be used for herbal medicine safety
nclude case control and cohort studies. These can be used to test
ypotheses developed after signals are detected using spontaneous
eports. One such signal was identiﬁed from the reports of possi-
le liver injury associated with the use of Chinese herbs (Perharic
t al., 1995; McRae et al., 2002). A pilot case control study was used
o demonstrate that there was no increased association with liver
njury and any individual herb (Shaw, 2010b).  As yet these methods
ave been under-utilised for herbal medicines.
. Herbal practitioners
Herbal practitioners are potentially a useful source of informa-
ion on ADRs but with varying levels of professional regulation
n Europe they are not necessarily recognised as ADR reporters.
ome herbal practitioner organisations have established their own
eporting schemes but these are not necessarily linked to ofﬁcial
gencies. There are beneﬁts to reporting by trained herbal practi-
ioners. They are educated in the use of the medicinal herbs and
hould know actions and potential toxicity of the herb and be
ble to identify unexpected effects of the treatment. Herbal pre-
criptions are routinely modiﬁed to reduce side effects or improve
esponses. Although some effects may  be minor sometimes non-
peciﬁc symptoms may  indicate a more serious illness (such as
iredness and liver dysfunction). In Europe they may  treat rela-
ively low numbers of patients so may  not recognise rare adverse
vents. In countries where there is limited recognition or lack of
rofessional standing of herbal practice then practitioners are likely
o be less conﬁdent about reporting suspected ADRS. Clear deﬁni-
ions of reportable ADRs need to be deﬁned and harmonised across
urisdictions.
. Minimum requirements for ADRs
Various groups have produced guidelines for reporting adverse
vents and clinical trials (Gagnier et al., 2006; Kelly et al., 2007)
ncluding herbal products. The requirements for case reports
nclude essential case details: patient demographics (age, gen-
er) relevant medical history, symptoms, abnormal laboratory
esults, drug identiﬁcation, reason for use, dose, time course (dura-
ion of use, onset of symptoms) and details of adverse event.acology 140 (2012) 513– 518 517
For manufactured herbal products they include product name,
producer, batch number, type and concentration of extract and
concentration of any standardised constituents. Botanical iden-
tiﬁcation only includes Latin scientiﬁc name, plant parts and
preparation (herb or extract). These guidelines are however not
adequate for herbal medicines supplied as complex formulas or for
most traditional medicines such as Chinese or Ayurvedic medicine
as used in Europe.
Any ADR report should list the name as given on the
label/prescription. If there is additional information on identity
based on morphological or chemical investigation then the source
of this detail should be included. Traditional herbal formulas (and
even products) do not necessarily include the botanical name. The
Latin scientiﬁc name cannot be assumed from the common or drug
name and is only accurate if the plant material has been authen-
ticated. If the plant identity has been veriﬁed, then the scientiﬁc
name, author, plant part and processing should be given. Details
of processing of the herbal material before use (e.g. in Chinese
medicine, stir frying, steaming) are required as this can dramati-
cally change the chemical proﬁle or bioavailability of the herbs.
Other useful details for any evaluation are reason for use and
diagnosis by the herbal practitioner. This should be based on sup-
portive information from the practitioner. Involving the herbal
practitioner in any assessment of suspected adverse reaction can
provide useful background or understanding of the use of the herbs.
Accurate adverse reaction reports are required so that real
adverse events can be identiﬁed and appropriate warnings and
guidelines can be given to practitioners and patients. If suspected
adverse reactions are not properly evaluated or the herbs have been
incorrectly identiﬁed then ‘safe’ or useful herbs may  be incorrectly
restricted. Accurate identiﬁcation of the medicinal herbs used is
essential when publishing case reports in the medical literature to
prevent misunderstandings.
As the use of herbal medicines has spread around the world
there is lack of information on the safety of herbs as used in
different patient populations that may  differ in essential param-
eters such as pharmacogenomics and metabolization proﬁles or
gut microﬂora composition and bioactivity. Effective pharmacovig-
ilance is essential to build up reliable information on the safety of
herbal medicines for the development of appropriate guidelines for
safe effective use.
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